Patent ID: 11903994
Assignee: APELLIS PHARMACEUTICALS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A

Claim 0:
1. A method of treating a subject in need of treatment for a complement-mediated eye disorder, the method comprising intravitreally administering about 15 mg of a long-acting compstatin analog (LACA) monthly or every other month to the eye of the subject, wherein
(a) the LACA comprises a PEG having an average molecular weight of 40 kD attached to two compstatin analog moieties, wherein
each compstatin analog moiety comprises a cyclic peptide having the amino acid sequence as set forth in SEQ ID NO: 28 extended by a lysine residue at the C-terminus, wherein the lysine residue is separated from the cyclic portion of the peptide by an 8-amino-3,6-dioxaoctanoic acid (AEEAc) spacer;
wherein each end of the PEG is linked to the amino group of the side chain of the lysine residue of one of the compstatin analog moieties by way of a carbamate; and

(b) the complement-mediated eye disorder is geographic atrophy.